Home/Biosimilar Atlas/Companies/Apotex

Apotex

Biosimilar developer, Canada. 3 development products across 3 molecules: aflibercept, bevacizumab, denosumab.

First approval in the Atlas: Sep 2021, Bambevi, bevacizumab (HC)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved3
CDSCOproducts approved0
EDEproducts registered0
Connections
3molecules3products1 of 7markets0candidates in trials8companies on the same molecules

About Apotex

Apotex, Canada's largest generics company, has built a line of biosimilars for the Canadian market with no counterpart elsewhere: bevacizumab in 2021, aflibercept and denosumab in 2025 and 2026. It also sold Intas's pegfilgrastim and filgrastim in Canada. Apotex does not name the developers of its own products.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AfliberceptAflivu····Jun 2025··1/7
BevacizumabBambevi····Sep 2021··1/7
DenosumabDenoza····Mar 2026··1/7

Month shown is the first approval or registration of that product in that market.

Also holds or markets

Products developed by another company for which Apotex is the licence holder or applicant in one or more markets.

MoleculeBrandMarketHolder or applicantApprovedDeveloper
FilgrastimGrastofilHCApotex INCDec 2015Intas Pharmaceuticals (Apotex)
PegfilgrastimLapelgaHCApotex INCApr 2018Intas Pharmaceuticals

Companies on the same molecules

Developers whose portfolios overlap most with Apotex, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsThree shared molecules: aflibercept, bevacizumab, denosumab9 molecules in its portfolioCelltrionThree shared molecules: aflibercept, bevacizumab, denosumab10 molecules in its portfolioSamsung BioepisThree shared molecules: aflibercept, bevacizumab, denosumab10 molecules in its portfolioAlvotechTwo shared molecules: aflibercept, denosumab5 molecules in its portfolioAmgenTwo shared molecules: aflibercept, bevacizumab8 molecules in its portfolioEnzene BiosciencesTwo shared molecules: bevacizumab, denosumab6 molecules in its portfolioFuji PharmaTwo shared molecules: aflibercept, denosumab5 molecules in its portfolioHeteroTwo shared molecules: bevacizumab, denosumab5 molecules in its portfolio

Chronology

Compare Apotex with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.